2024-03-11 LIDR Meeting Notes

Hung Luu

Children’s

Riki Merrick

Vernetzt, APHL

Andrea Pitkus

UW

Pam Banning

3M - Solventum

Xavier Gansel

Biomerieux

Amy McCormick

Epic

Dan Rutz

Epic

Rob Rae

CAP

Rob Hausam

Hausam Consulting

Sandy Jones

CDC

Stan Huff

Graphite

Ed Heierman

Abbott / IICC

Andrew Quinn

Laurent Lardin

Biomerieux

Anthony Killeen

UMN

Craig Collom

Marti Velezis

 Sonrisa / FDA

Walter Sujansky

FDA

Susan Downer

JMC

Ralf Herzog

Roche

Cornelia Felder

Roche

Daniel Golson

JMC

Andrea Prada

JMC

Maria Sagat

 CAP

Raja Cholan

FDA

Russ Ott

FDA

Akila Namasivayam

FDA

Desiree Mustaquim

CDC

Reviewing minutes from the last call - Action Item Follow up

• Pull out the definitions from LIVD for test kit and equipment and put here: SHIELD Glossary

  • Review operational definition of “equivalence”

• Outreach to Dr. DeBaca

  • Hung will check for more info and maybe see, if she could participate in SHIELD

• Waiting for response from Ed

• Keep updating the googlesheet: Potassium LIVD data

• Shared Reportable Conditions LIVD google sheet for crowdsourcing with CSTE - added sign up sheet for PHAs to specific conditions and see how that develops

• Have LIVD File Repository Requirements

  Have draft budget (for setting up a web-based database and yearly maintenance): https://aphlinformatics.atlassian.net/wiki/download/attachments/915407143/LIDR - Budget.xlsx?api=v2

• Sign up for sections to provide draft content on the LIDR White Paper

• Review LIDR Use Cases and sign up to lead one of these

• Define next steps to migrate existing LIVD files into FHIR LIVD catalog format and find a FHIR server to host

Call Schedule

send OOO via chat or email

LIDR Elements Discussion

Review LIDR White Paper

 Went over current draft of the White Paper

• Members to Review and offer comments on draft document

• Suggestion to collapse Functional and Non-Functional Requirements into one Requirements Section

• Stan to further refine the Requirements section outline

• Explicitly state that there will be some LIDR entries provided by IVD manufacturers and some entries that will be provided by LIDR Administrators such as results derived from equations (e.g., eGFR) and results with clinical context (e.g., 24-hour urine)

• Question on how to collaborate with TEFCA Lab Tiger Team Interoperability Efforts

  • There seems to be little opportunity to influence document given cumbersome method available for providing comments

  • Lack of emphasis on the comparability of results as a interoperability barrier that needs to be addressed

  • Track work of TEFCA Tiger Team to ensure efforts are complementary and not contradictory

ACTION ITEMS

Please see the action items at top of this page - Next deliverable is White paper draft by end of this month

And we need to prioritize the use cases, so that we can finalize the requirements for the first phase of LIDR, which need to be included in the White paper

Next call

Monday 3/18/2024 9 - 10 AM ET

Adjourned

10:00 AM ET